BROVANA^® (arformoterol tartrate): Reduced rescue medication use
37% reduction in daily use of rescue albuterol^*1

Data from 2 identical, 12-week, double-blind, placebo-controlled, randomized, multicenter trials assessing the efficacy and tolerability of nebulized BROVANA^® (arformoterol tartrate) Inhalation Solution 15 mcg (n=285) vs placebo (n=289) in patients with COPD.²

* Data are pooled from clinical trials A and B over 12 weeks.

COPD patients saw 37% reduction in daily use of supplemental ipratropium^*1

Data from 2 identical, 12-week, double-blind, placebo-controlled, randomized, multicenter trials assessing the efficacy and tolerability of nebulized BROVANA^® (arformoterol tartrate) Inhalation Solution 15 mcg (n=285) vs placebo (n=289) in patients with COPD.¹

* Data are pooled from clinical trials A and B over 12 weeks.

BROVANA^® (arformoterol tartrate) is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.

BROVANA^® (arformoterol tartrate) should not be used in conjunction with other inhaled, long-acting beta₂-agonists.

BROVANA^® (arformoterol tartrate) should not be used with other medications containing long-acting beta₂-agonists.

COPD patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.